Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
about
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patientsThe therapeutic role of niacin in dyslipidemia managementPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The AtheComparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic PatientsAdenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoproteinChanges in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.CETP Inhibition: does the future look promising?Dyslipidemias in the prevention of cardiovascular disease: risks and causality.Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
P2860
Q28244205-3585822B-A1EF-4FB3-B8EA-69D9B3C66C8AQ28304559-5D4F2076-3E73-4AEA-AB2F-9F65AB077461Q33972551-B5E81B04-8955-46D8-B36B-13CB9B8EFA70Q34162072-C204D968-4B64-4A8C-B605-4887239B8938Q35060328-47865CD0-7592-403B-8CA2-350199E8C10FQ36637890-2018F2B4-7E0B-4BDC-A94D-D923A9D9B1B7Q36989495-400FB617-B705-484B-B486-A14B7541EC99Q37310485-2945E86A-2771-43C7-9D6A-D656C51A518CQ37930463-F6D49C75-6ACA-4842-86B7-D349F3A5C64EQ38042396-89D79F6D-1881-4566-B745-AD7C71ABDC8DQ38661093-C67789B9-B2B6-47D9-AF0C-069672ADA480Q38765419-4C00AD16-745E-497A-A229-A36D41AEDA72Q39453691-BFB3F7F6-450E-4F4A-A7BE-6E91DD5CBB69
P2860
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@ast
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@en
type
label
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@ast
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@en
prefLabel
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@ast
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@en
P2093
P2860
P1476
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
@en
P2093
B Greg Brown
Marian C Cheung
Xue-Qiao Zhao
P2860
P356
10.1016/J.JACL.2007.02.004
P407
P577
2007-02-15T00:00:00Z